Trial Outcomes & Findings for Temporal Trends of Thrombolysis Treatment in Chinese Acute Ischemic Stroke (AIS) Patients From 2007-2017: Analysis of China National Stroke Registry (CNSR) I, II, and III; CTP-Draft Review Performed; (NCT NCT04290494)
NCT ID: NCT04290494
Last Updated: 2021-11-05
Results Overview
The percentage of patients who received Intravenous Recombinant Plasminogen Activator (IV-rtPA) treatment within 3 hours of symptom onset among patients eligible for intravenous thrombolytics (IVT) who arrived at the hospital within 2 hours since symptom onset was reported.
COMPLETED
42188 participants
From 2007 to 2017, up to 10 years before this study started.
2021-11-05
Participant Flow
This non-interventional study was based on Chinese acute ischemic stroke patients who had treatment from 2007 to 2017 from the existing data of the China National Stroke Registry (CNSR) I, II, and III to investigate the temporal trends of thrombolysis treatment in Chinese acute ischemic stroke patients.
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) I, II, and III with treatment from 2007 to 2017 were included.
Participant milestones
| Measure |
China National Stroke Registry (CNSR) I (2007 to 2008)
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) I (data in this existing database were collected during 2007-2008) were included in this group.
|
China National Stroke Registry (CNSR) II (2012 to 2013)
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) II (data in this existing database were collected during 2012-2013) were included in this group.
|
China National Stroke Registry (CNSR) III (2015 to 2017)
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) III (data in this existing database were collected during 2015-2017) were included in this group.
|
|---|---|---|---|
|
Overall Study
STARTED
|
10968
|
17823
|
13397
|
|
Overall Study
COMPLETED
|
10968
|
17823
|
13397
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Race and Ethnicity were not collected from any participant.
Baseline characteristics by cohort
| Measure |
China National Stroke Registry (CNSR) I (2007 to 2008)
n=10968 Participants
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) I (data in this existing database were collected during 2007-2008) were included in this group.
|
China National Stroke Registry (CNSR) II (2012 to 2013)
n=17823 Participants
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) II (data in this existing database were collected during 2012-2013) were included in this group.
|
China National Stroke Registry (CNSR) III (2015 to 2017)
n=13397 Participants
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) III (data in this existing database were collected during 2015-2017) were included in this group.
|
Total
n=42188 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Continuous
|
63.5 Years
STANDARD_DEVIATION 11.1 • n=10968 Participants
|
62.9 Years
STANDARD_DEVIATION 10.8 • n=17823 Participants
|
61.2 Years
STANDARD_DEVIATION 10.4 • n=13397 Participants
|
62.5 Years
STANDARD_DEVIATION 10.8 • n=42188 Participants
|
|
Sex: Female, Male
Female
|
4053 Participants
n=10968 Participants
|
6350 Participants
n=17823 Participants
|
4114 Participants
n=13397 Participants
|
14517 Participants
n=42188 Participants
|
|
Sex: Female, Male
Male
|
6915 Participants
n=10968 Participants
|
11473 Participants
n=17823 Participants
|
9283 Participants
n=13397 Participants
|
27671 Participants
n=42188 Participants
|
|
Race and Ethnicity Not Collected
|
—
|
—
|
—
|
0 Participants
Race and Ethnicity were not collected from any participant.
|
PRIMARY outcome
Timeframe: From 2007 to 2017, up to 10 years before this study started.Population: All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) phase I to phase III with treatment from 2007 to 2017. Only those patients eligible for intravenous thrombolytics (IVT) who arrived at the hospital within 2 hours since symptom onset were included in the analysis.
The percentage of patients who received Intravenous Recombinant Plasminogen Activator (IV-rtPA) treatment within 3 hours of symptom onset among patients eligible for intravenous thrombolytics (IVT) who arrived at the hospital within 2 hours since symptom onset was reported.
Outcome measures
| Measure |
China National Stroke Registry (CNSR) I (2007 to 2008)
n=866 Participants
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) I (data in this existing database were collected during 2007-2008) were included in this group.
|
China National Stroke Registry (CNSR) II (2012 to 2013)
n=2214 Participants
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) II (data in this existing database were collected during 2012-2013) were included in this group.
|
China National Stroke Registry (CNSR) III (2015 to 2017)
n=1679 Participants
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) III (data in this existing database were collected during 2015-2017) were included in this group.
|
|---|---|---|---|
|
Percentage of Patients Who Received Intravenous Recombinant Plasminogen Activator (IV-rtPA) Treatment Within 3 Hours of Symptom Onset Among 2 Hours Intravenous Thrombolytics (IVT) Eligible Patients
|
11.66 Percentage of participants
Interval 9.53 to 13.8
|
10.66 Percentage of participants
Interval 9.37 to 11.94
|
28.77 Percentage of participants
Interval 26.6 to 30.93
|
PRIMARY outcome
Timeframe: From 2007 to 2017, up to 10 years before this study started.Population: All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) phase I to phase III with treatment from 2007 to 2017. Only those patients eligible for intravenous thrombolytics (IVT) who arrived at the hospital within 3.5 hours since symptom onset were included in the analysis.
The percentage of patients who received Intravenous Recombinant Plasminogen Activator (IV-rtPA) treatment within 4.5 hours of symptom onset among patients eligible for intravenous thrombolytics (IVT) who arrived at the hospital within 3.5 hours since symptom onset was reported.
Outcome measures
| Measure |
China National Stroke Registry (CNSR) I (2007 to 2008)
n=1271 Participants
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) I (data in this existing database were collected during 2007-2008) were included in this group.
|
China National Stroke Registry (CNSR) II (2012 to 2013)
n=3684 Participants
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) II (data in this existing database were collected during 2012-2013) were included in this group.
|
China National Stroke Registry (CNSR) III (2015 to 2017)
n=2787 Participants
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) III (data in this existing database were collected during 2015-2017) were included in this group.
|
|---|---|---|---|
|
Percentage of Patients Who Received Intravenous Recombinant Plasminogen Activator (IV-rtPA) Treatment Within 4.5 Hours of Symptom Onset Among 3.5 Hours Intravenous Thrombolytics (IVT) Eligible Patients
|
13.53 Percentage of participants
Interval 11.65 to 15.41
|
7.11 Percentage of participants
Interval 6.28 to 7.94
|
33.44 Percentage of participants
Interval 31.69 to 35.19
|
SECONDARY outcome
Timeframe: From 2007 to 2017, up to 10 years before this study started.Population: All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) phase I to phase III with treatment from 2007 to 2017.
Percentage of patients who arrived at hospital within 2 hours of symptom onset and who received Intravenous Recombinant Plasminogen Activator (IV-rtPA) treatment within 3 hours of symptom onset among all eligible patients was reported.
Outcome measures
| Measure |
China National Stroke Registry (CNSR) I (2007 to 2008)
n=10968 Participants
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) I (data in this existing database were collected during 2007-2008) were included in this group.
|
China National Stroke Registry (CNSR) II (2012 to 2013)
n=17823 Participants
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) II (data in this existing database were collected during 2012-2013) were included in this group.
|
China National Stroke Registry (CNSR) III (2015 to 2017)
n=13397 Participants
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) III (data in this existing database were collected during 2015-2017) were included in this group.
|
|---|---|---|---|
|
Percentage of Patients Who Arrived at Hospital Within 2 Hours of Symptom Onset and Who Received Intravenous Recombinant Plasminogen Activator (IV-rtPA) Treatment Within 3 Hours of Symptom Onset Among All Eligible Patients
|
0.92 Percentage of participants
Interval 0.74 to 1.1
|
1.32 Percentage of participants
Interval 1.16 to 1.49
|
3.61 Percentage of participants
Interval 3.29 to 3.92
|
SECONDARY outcome
Timeframe: From 2007 to 2017, up to 10 years before this study started.Population: All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) phase I to phase III with treatment from 2007 to 2017.
Percentage of patients who arrived at hospital within 3.5 hours of symptom onset and who received Intravenous Recombinant Plasminogen Activator (IV-rtPA) treatment within 4.5 hours of symptom onset among all eligible patients was reported.
Outcome measures
| Measure |
China National Stroke Registry (CNSR) I (2007 to 2008)
n=10968 Participants
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) I (data in this existing database were collected during 2007-2008) were included in this group.
|
China National Stroke Registry (CNSR) II (2012 to 2013)
n=17823 Participants
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) II (data in this existing database were collected during 2012-2013) were included in this group.
|
China National Stroke Registry (CNSR) III (2015 to 2017)
n=13397 Participants
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) III (data in this existing database were collected during 2015-2017) were included in this group.
|
|---|---|---|---|
|
Percentage of Patients Who Arrived at Hospital Within 3.5 Hours of Symptom Onset and Who Received Intravenous Recombinant Plasminogen Activator (IV-rtPA) Treatment Within 4.5 Hours of Symptom Onset Among All Eligible Patients
|
1.57 Percentage of participants
Interval 1.34 to 1.8
|
1.47 Percentage of participants
Interval 1.29 to 1.65
|
6.96 Percentage of participants
Interval 6.53 to 7.39
|
SECONDARY outcome
Timeframe: From arrival at the hospital until the administration of Intravenous Recombinant Plasminogen Activator, up to 170 minutes.Population: All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) phase I to phase III with treatment from 2007 to 2017. Only those patients who were treated with Intravenous Recombinant Plasminogen Activator (IV-rtPA) within 3 hours since symptom onset were included in the analysis.
The door to needle (DTN) time (time between arrival at hospital and the administration of Intravenous Recombinant Plasminogen Activator (IV-rtPA) treatment) among patients who were treated with Intravenous Recombinant Plasminogen Activator (IV-rtPA) within 3 hours since symptom onset was reported.
Outcome measures
| Measure |
China National Stroke Registry (CNSR) I (2007 to 2008)
n=101 Participants
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) I (data in this existing database were collected during 2007-2008) were included in this group.
|
China National Stroke Registry (CNSR) II (2012 to 2013)
n=236 Participants
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) II (data in this existing database were collected during 2012-2013) were included in this group.
|
China National Stroke Registry (CNSR) III (2015 to 2017)
n=483 Participants
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) III (data in this existing database were collected during 2015-2017) were included in this group.
|
|---|---|---|---|
|
The Door to Needle (DTN) Time (Time Between Arrival at Hospital and the Administration of Intravenous Recombinant Plasminogen Activator (IV-rtPA) Treatment) Among 3 Hours IV-rtPA Treated Patients
|
90.0 minutes
Interval 60.0 to 120.0
|
100.0 minutes
Interval 74.0 to 113.0
|
58.0 minutes
Interval 38.0 to 77.0
|
SECONDARY outcome
Timeframe: From 2007 to 2017, up to 10 years before this study started.Population: All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) phase I to phase III with treatment from 2007 to 2017. Only those patients who were treated with Intravenous Recombinant Plasminogen Activator (IV-rtPA) within 3 hours since symptom onset were included in the analysis.
The percentage of patients with door to needle (DTN) time (time between arrival at hospital and the administration of Intravenous Recombinant Plasminogen Activator (IV-rtPA) treatment) ≤ 60 minutes among patients who were treated with Intravenous Recombinant Plasminogen Activator (IV-rtPA) within 3 hours since symptom onset was reported.
Outcome measures
| Measure |
China National Stroke Registry (CNSR) I (2007 to 2008)
n=101 Participants
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) I (data in this existing database were collected during 2007-2008) were included in this group.
|
China National Stroke Registry (CNSR) II (2012 to 2013)
n=236 Participants
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) II (data in this existing database were collected during 2012-2013) were included in this group.
|
China National Stroke Registry (CNSR) III (2015 to 2017)
n=483 Participants
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) III (data in this existing database were collected during 2015-2017) were included in this group.
|
|---|---|---|---|
|
Percentage of Patients With Door to Needle (DTN) Time (Time Between Arrival at Hospital and the Administration of Intravenous Recombinant Plasminogen Activator (IV-rtPA) Treatment) ≤ 60 Minutes Among 3 Hours IV-rtPA Treated Patients
|
28.71 Percentage of participants
Interval 19.89 to 37.54
|
12.29 Percentage of participants
Interval 8.1 to 16.48
|
59.21 Percentage of participants
Interval 54.83 to 63.6
|
SECONDARY outcome
Timeframe: From symptom onset until arrival at the hospital, up to 120 minutes.Population: All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) phase I to phase III with treatment from 2007 to 2017. Only those patients who were treated with Intravenous Recombinant Plasminogen Activator (IV-rtPA) within 3 hours since symptom onset were included in the analysis.
Time between symptom onset and arrival at hospital among patients who were treated with Intravenous Recombinant Plasminogen Activator (IV-rtPA) within 3 hours since symptom onset was reported.
Outcome measures
| Measure |
China National Stroke Registry (CNSR) I (2007 to 2008)
n=101 Participants
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) I (data in this existing database were collected during 2007-2008) were included in this group.
|
China National Stroke Registry (CNSR) II (2012 to 2013)
n=236 Participants
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) II (data in this existing database were collected during 2012-2013) were included in this group.
|
China National Stroke Registry (CNSR) III (2015 to 2017)
n=483 Participants
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) III (data in this existing database were collected during 2015-2017) were included in this group.
|
|---|---|---|---|
|
Time Between Symptom Onset and Arrival at Hospital Among 3 Hours Intravenous Recombinant Plasminogen Activator (IV-rtPA) Treated Patients
|
60.0 minutes
Interval 32.0 to 90.0
|
59.0 minutes
Interval 43.0 to 75.0
|
69.0 minutes
Interval 50.0 to 93.0
|
SECONDARY outcome
Timeframe: From symptom onset until administration of Intravenous Recombinant Plasminogen Activator, up to 180 minutes.Population: All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) phase I to phase III with treatment from 2007 to 2017. Only those patients who were treated with Intravenous Recombinant Plasminogen Activator (IV-rtPA) within 3 hours since symptom onset were included in the analysis.
Time between symptom onset and the administration of Intravenous Recombinant Plasminogen Activator (IV-rtPA) treatment among patients who were treated with Intravenous Recombinant Plasminogen Activator (IV-rtPA) within 3 hours since symptom onset was reported.
Outcome measures
| Measure |
China National Stroke Registry (CNSR) I (2007 to 2008)
n=101 Participants
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) I (data in this existing database were collected during 2007-2008) were included in this group.
|
China National Stroke Registry (CNSR) II (2012 to 2013)
n=236 Participants
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) II (data in this existing database were collected during 2012-2013) were included in this group.
|
China National Stroke Registry (CNSR) III (2015 to 2017)
n=483 Participants
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) III (data in this existing database were collected during 2015-2017) were included in this group.
|
|---|---|---|---|
|
Time Between Symptom Onset and the Administration of Intravenous Recombinant Plasminogen Activator (IV-rtPA) Treatment Among 3 Hours IV-rtPA Treated Patients
|
150.0 minutes
Interval 138.0 to 170.0
|
156.0 minutes
Interval 141.0 to 165.0
|
134.0 minutes
Interval 108.0 to 155.0
|
SECONDARY outcome
Timeframe: From arrival at the hospital until the administration of Intravenous Recombinant Plasminogen Activator, up to 247 minutes.Population: All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) phase I to phase III with treatment from 2007 to 2017. Only those patients who were treated with Intravenous Recombinant Plasminogen Activator (IV-rtPA) within 4.5 hours since symptom onset were included in the analysis.
The door to needle (DTN) time (time between arrival at hospital and the administration of Intravenous Recombinant Plasminogen Activator (IV-rtPA) treatment) among patients who were treated with Intravenous Recombinant Plasminogen Activator (IV-rtPA) within 4.5 hours since symptom onset was reported.
Outcome measures
| Measure |
China National Stroke Registry (CNSR) I (2007 to 2008)
n=172 Participants
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) I (data in this existing database were collected during 2007-2008) were included in this group.
|
China National Stroke Registry (CNSR) II (2012 to 2013)
n=262 Participants
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) II (data in this existing database were collected during 2012-2013) were included in this group.
|
China National Stroke Registry (CNSR) III (2015 to 2017)
n=932 Participants
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) III (data in this existing database were collected during 2015-2017) were included in this group.
|
|---|---|---|---|
|
The Door to Needle (DTN) Time (Time Between Arrival at Hospital and the Administration of Intravenous Recombinant Plasminogen Activator (IV-rtPA) Treatment) Among 4.5 Hours IV-rtPA Treated Patients
|
94.0 minutes
Interval 60.0 to 130.0
|
95.0 minutes
Interval 72.0 to 112.0
|
60.0 minutes
Interval 38.0 to 84.5
|
SECONDARY outcome
Timeframe: From 2007 to 2017, up to 10 years before this study started.Population: All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) phase I to phase III with treatment from 2007 to 2017. Only those patients who were treated with Intravenous Recombinant Plasminogen Activator (IV-rtPA) within 4.5 hours since symptom onset were included in the analysis.
The percentage of patients with door to needle (DTN) time (time between arrival at hospital and the administration of Intravenous Recombinant Plasminogen Activator (IV-rtPA) treatment) ≤ 60 minutes among patients who were treated with Intravenous Recombinant Plasminogen Activator (IV-rtPA) within 4.5 hours since symptom onset was reported.
Outcome measures
| Measure |
China National Stroke Registry (CNSR) I (2007 to 2008)
n=172 Participants
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) I (data in this existing database were collected during 2007-2008) were included in this group.
|
China National Stroke Registry (CNSR) II (2012 to 2013)
n=262 Participants
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) II (data in this existing database were collected during 2012-2013) were included in this group.
|
China National Stroke Registry (CNSR) III (2015 to 2017)
n=932 Participants
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) III (data in this existing database were collected during 2015-2017) were included in this group.
|
|---|---|---|---|
|
Percentage of Patients With Door to Needle (DTN) Time (Time Between Arrival at Hospital and the Administration of Intravenous Recombinant Plasminogen Activator (IV-rtPA) Treatment) ≤ 60 Minutes Among 4.5 Hours IV-rtPA Treated Patients
|
26.74 Percentage of participants
Interval 20.13 to 33.36
|
13.36 Percentage of participants
Interval 9.24 to 17.48
|
53.43 Percentage of participants
Interval 50.23 to 56.64
|
SECONDARY outcome
Timeframe: From symptom onset until arrival at the hospital, up to 210 minutes.Population: All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) phase I to phase III with treatment from 2007 to 2017. Only those patients who were treated with Intravenous Recombinant Plasminogen Activator (IV-rtPA) within 4.5 hours since symptom onset were included in the analysis.
Time between symptom onset and arrival at hospital among patients who were treated with Intravenous Recombinant Plasminogen Activator (IV-rtPA) within 4.5 hours since symptom onset was reported
Outcome measures
| Measure |
China National Stroke Registry (CNSR) I (2007 to 2008)
n=172 Participants
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) I (data in this existing database were collected during 2007-2008) were included in this group.
|
China National Stroke Registry (CNSR) II (2012 to 2013)
n=262 Participants
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) II (data in this existing database were collected during 2012-2013) were included in this group.
|
China National Stroke Registry (CNSR) III (2015 to 2017)
n=932 Participants
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) III (data in this existing database were collected during 2015-2017) were included in this group.
|
|---|---|---|---|
|
Time Between Symptom Onset and Arrival at Hospital Among 4.5 Hours Intravenous Recombinant Plasminogen Activator (IV-rtPA) Treated Patients
|
75.0 minutes
Interval 42.5 to 110.0
|
59.0 minutes
Interval 45.0 to 84.0
|
100.0 minutes
Interval 60.0 to 140.0
|
SECONDARY outcome
Timeframe: From symptom onset until the administration of Intravenous Recombinant Plasminogen Activator, up to 270 minutes.Population: All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) phase I to phase III with treatment from 2007 to 2017. Only those patients who were treated with Intravenous Recombinant Plasminogen Activator (IV-rtPA) within 4.5 hours since symptom onset were included in the analysis.
Time between symptom onset and the administration of Intravenous Recombinant Plasminogen Activator (IV-rtPA) treatment among patients who were treated with Intravenous Recombinant Plasminogen Activator (IV-rtPA) within 4.5 hours since symptom onset was reported
Outcome measures
| Measure |
China National Stroke Registry (CNSR) I (2007 to 2008)
n=172 Participants
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) I (data in this existing database were collected during 2007-2008) were included in this group.
|
China National Stroke Registry (CNSR) II (2012 to 2013)
n=262 Participants
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) II (data in this existing database were collected during 2012-2013) were included in this group.
|
China National Stroke Registry (CNSR) III (2015 to 2017)
n=983 Participants
All eligible patients who met all inclusion and none of the exclusion criteria from the existing data of China National Stroke Registry (CNSR) III (data in this existing database were collected during 2015-2017) were included in this group.
|
|---|---|---|---|
|
Time Between Symptom Onset and the Administration of Intravenous Recombinant Plasminogen Activator (IV-rtPA) Treatment Among 4.5 Hours IV-rtPA Treated Patients
|
175.0 minutes
Interval 150.0 to 200.0
|
159.0 minutes
Interval 144.0 to 169.0
|
170.0 minutes
Interval 132.0 to 210.0
|
Adverse Events
China National Stroke Registry (CNSR) I (2007 to 2008)
China National Stroke Registry (CNSR) II (2012 to 2013)
China National Stroke Registry (CNSR) III (2015 to 2017)
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Boehringer Ingelheim Call Center
Boehringer Ingelheim
Results disclosure agreements
- Principal investigator is a sponsor employee Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.
- Publication restrictions are in place
Restriction type: OTHER